RxDoctor Payments DataLook up a doctor →

Sabino Torre, MD

Cardiovascular Disease · West Orange, NJNPI 1518967165

Payments from drug & device makers

$97,993in general payments, 2019–2025

Across 584 payments — averaging $167.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$50K
  • E.r. Squibb & Sons, L.L.C.$20K
  • Edwards Lifesciences$13K
  • Pfizer$4K
  • Novartis$3K
  • Abbott$2K
  • plus $6K from 41 others
$1,605in research payments, 2019–2025

Across 1 payment — averaging $1605.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$2K

What the payments were for

  • Consulting fees$9,90017%
  • Speaking & faculty fees$19,48834%
  • Grants$490%
  • Travel & lodging$14,83626%
  • Food & beverage$12,35322%
  • Education$240%
  • Other$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,993 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$287,817
Medicare patients
1,670
Services billed
4,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$147,040
EntrestoSacubitril/Valsartan55$68,000
XareltoRivaroxaban26$26,148
Repatha SureclickEvolocumab11$15,407
Metoprolol Succinate207$3,679
Rosuvastatin Calcium148$2,420
Atorvastatin Calcium180$2,193
Olmesartan Medoxomil84$1,472
Ezetimibe38$1,451
Amlodipine Besylate183$1,423
ClopidogrelClopidogrel Bisulfate76$1,294
Carvedilol54$676
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$615
Torsemide37$571
Losartan Potassium52$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$3,802$147,040141 claims
NovartisEntresto$2,830$68,00055 claims
Johnson & JohnsonXarelto$371$26,14826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →